Miruvor
Sign up
The short answer

What studies of l-carnitine found

38papers on l-carnitine
75people in 2 studies testing l-carnitine alone
1randomised trial, the strongest kind of study

At a glance, by condition

ME/CFS: B May help

Based on the strongest evidence, the placebo trial (low certainty): 5 findings, all B.

10 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: L-carnitine may help for ME/CFS, but the evidence is still limited. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 38 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. L-carnitine · ME/CFS is hereB
    May helpImprovement, low certainty
  3. C
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

ME/CFS

Symptoms

Fatigue2 studies · 75 people took l-carnitine Improvement B
Low certainty

Why this grade: Improvement, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (96 in all).

The placebo trial96 randomised · 180-day period · 2 g twice-a-day, throughout a 180-day period

Fatigue improved more than in the comparison group.

L-carnitine may reduce fatigue in ME/CFS. Improvement · low certainty B

  • Some concerns about bias (RoB 2)
  • Few people (96 in all)

Studies with no comparison group30 in the study · 28 started · 28 with outcome data · 2 months · | g 3 times a day

No clear change in fatigue.

The evidence is very uncertain about the effect of L-carnitine on fatigue in ME/CFS. Little or no difference · very low certainty D

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (27 in all)

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): Chalder Fatigue Scale (CFQ), better.

Shown, not counted: l-carnitine was given together with other treatments.

Combination: Folate / folic acid supplements + Vitamin B6 (pyridoxine, P5P) + Vitamin B12 + L-carnitine + Midodrine + Methylphenidate (Ritalin, Concerta)1 in the study

Comorbidity of chronic fatigue syndrome, postural tachycardia syndrome, and narcolepsy with 5,10-methylenetetrahydrofolate reductase (MTHFR) mutation in an adolescent: a case report (2021): drowsiness and fatigue, better (not tested).

Shown, not counted: l-carnitine was given together with other treatments.

See the 2 studies
  1. Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue. (2008)

    People in the study
    96 randomised
    Dose
    2 g twice-a-day, throughout a 180-day period
    Outcome
    physical fatigue
    Effect
    better
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  2. Amantadine and L-carnitine treatment of Chronic Fatigue Syndrome. (1997)

    People in the study
    30 in the study · 28 started · 28 with outcome data
    Dose
    | g 3 times a day
    Outcome
    FSS Fatigue Severity Scale
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Cognition (brain fog)1 study · 48 people took l-carnitine Improvement B
Low certainty

Why this grade: Improvement, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (96 in all).

The placebo trial96 randomised · 180-day period · 2 g twice-a-day, throughout a 180-day period

Cognition (brain fog) improved more than in the comparison group.

L-carnitine may improve cognition (brain fog) in ME/CFS. Improvement · low certainty B

  • Some concerns about bias (RoB 2)
  • Few people (96 in all)

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): memory, item 11, and problems starting things, item 4, no clear difference.

Shown, not counted: l-carnitine was given together with other treatments.

See the 1 study
  1. Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue. (2008)

    People in the study
    96 randomised
    Dose
    2 g twice-a-day, throughout a 180-day period
    Outcome
    MMSE mini mental state examination
    Effect
    better
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Pain1 study · 48 people took l-carnitine Improvement B
Low certainty

Why this grade: Improvement, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (96 in all).

The placebo trial96 randomised · 180-day period · 2 g twice-a-day, throughout a 180-day period

Pain improved more than in the comparison group.

L-carnitine may reduce pain in ME/CFS. Improvement · low certainty B

  • Some concerns about bias (RoB 2)
  • Few people (96 in all)
See the 1 study
  1. Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue. (2008)

    People in the study
    96 randomised
    Dose
    2 g twice-a-day, throughout a 180-day period
    Outcome
    muscle pain
    Effect
    better
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Post-exertional malaise1 study · 48 people took l-carnitine Improvement B
Low certainty

Why this grade: Improvement, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (96 in all).

The placebo trial96 randomised · 180-day period · 2 g twice-a-day, throughout a 180-day period

Post-exertional malaise improved more than in the comparison group.

L-carnitine may reduce post-exertional malaise in ME/CFS. Improvement · low certainty B

  • Some concerns about bias (RoB 2)
  • Few people (96 in all)
See the 1 study
  1. Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue. (2008)

    People in the study
    96 randomised
    Dose
    2 g twice-a-day, throughout a 180-day period
    Outcome
    prolonged fatigue after exercise
    Effect
    better
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Anxiety1 study · 27 people took l-carnitine Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (27 in all).

Studies with no comparison group30 in the study · 28 started · 28 with outcome data · 2 months · | g 3 times a day

Anxiety improved.

The evidence is very uncertain about the effect of L-carnitine on anxiety in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (27 in all)
See the 1 study
  1. Amantadine and L-carnitine treatment of Chronic Fatigue Syndrome. (1997)

    People in the study
    30 in the study · 28 started · 28 with outcome data
    Dose
    | g 3 times a day
    Outcome
    SCL-90-R Anxiety Symptom Checklist 90-R
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Depression1 study · 27 people took l-carnitine Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (27 in all).

Studies with no comparison group30 in the study · 28 started · 28 with outcome data · 2 months · | g 3 times a day

Depression improved.

The evidence is very uncertain about the effect of L-carnitine on depression in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (27 in all)

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): total MADRS score, no clear difference.

Shown, not counted: l-carnitine was given together with other treatments.

See the 1 study
  1. Amantadine and L-carnitine treatment of Chronic Fatigue Syndrome. (1997)

    People in the study
    30 in the study · 28 started · 28 with outcome data
    Dose
    | g 3 times a day
    Outcome
    SCL-90-R Depression Symptom Checklist 90-R
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Sleep1 study · 48 people took l-carnitine Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 96 people found no clear difference; a small benefit can't be ruled out.

The placebo trial96 randomised · 180-day period · 2 g twice-a-day, throughout a 180-day period

No clear difference in sleep.

The evidence is very uncertain about the effect of L-carnitine on sleep in ME/CFS. Little or no difference · very low certainty D

  • Some concerns about bias (RoB 2)
  • One trial of 96 people found no clear difference; a small benefit can't be ruled out

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): ISI, better.

Shown, not counted: l-carnitine was given together with other treatments.

Combination: Folate / folic acid supplements + Vitamin B6 (pyridoxine, P5P) + Vitamin B12 + L-carnitine + Midodrine + Methylphenidate (Ritalin, Concerta)1 in the study

Comorbidity of chronic fatigue syndrome, postural tachycardia syndrome, and narcolepsy with 5,10-methylenetetrahydrofolate reductase (MTHFR) mutation in an adolescent: a case report (2021): total sleep duration, better (not tested).

Shown, not counted: l-carnitine was given together with other treatments.

See the 1 study
  1. Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue. (2008)

    People in the study
    96 randomised
    Dose
    2 g twice-a-day, throughout a 180-day period
    Outcome
    sleep disorders
    Effect
    no clear difference
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Low mood or anxiety1 study · 27 people took l-carnitine Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (27 in all).

Studies with no comparison group30 in the study · 28 started · 28 with outcome data · 2 months · | g 3 times a day

No clear change in low mood or anxiety.

The evidence is very uncertain about the effect of L-carnitine on low mood or anxiety in ME/CFS. Little or no difference · very low certainty D

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (27 in all)
See the 1 study
  1. Amantadine and L-carnitine treatment of Chronic Fatigue Syndrome. (1997)

    People in the study
    30 in the study · 28 started · 28 with outcome data
    Dose
    | g 3 times a day
    Outcome
    SCL-90-R Hostility Symptom Checklist 90-R
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Daily functioning1 study · 48 people took l-carnitine Improvement B
Low certainty

Why this grade: Improvement, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (96 in all).

The placebo trial96 randomised · 180-day period · 2 g twice-a-day, throughout a 180-day period

Daily functioning improved more than in the comparison group.

L-carnitine may improve daily functioning in ME/CFS. Improvement · low certainty B

  • Some concerns about bias (RoB 2)
  • Few people (96 in all)

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): WSAS, no clear difference.

Shown, not counted: l-carnitine was given together with other treatments.

Combination: Folate / folic acid supplements + Vitamin B6 (pyridoxine, P5P) + Vitamin B12 + L-carnitine + Midodrine + Methylphenidate (Ritalin, Concerta)1 in the study

Comorbidity of chronic fatigue syndrome, postural tachycardia syndrome, and narcolepsy with 5,10-methylenetetrahydrofolate reductase (MTHFR) mutation in an adolescent: a case report (2021): school life and sleep rhythm, better (not tested).

Shown, not counted: l-carnitine was given together with other treatments.

See the 1 study
  1. Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue. (2008)

    People in the study
    96 randomised
    Dose
    2 g twice-a-day, throughout a 180-day period
    Outcome
    functional status physical functioning (PF) scale
    Effect
    better
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Overall symptoms1 study · 27 people took l-carnitine Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (27 in all).

Studies with no comparison group30 in the study · 28 started · 28 with outcome data · 2 months · | g 3 times a day

No clear change in overall symptoms.

The evidence is very uncertain about the effect of L-carnitine on overall symptoms in ME/CFS. Little or no difference · very low certainty D

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (27 in all)

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): CGI-I, better.

Shown, not counted: l-carnitine was given together with other treatments.

Combination: Dichloroacetate (DCA) + Thiamine / benfotiamine + CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + L-carnitine35 in the study

Why do some ME/CFS patients benefit from treatment with sodium dichloroacetate, but others do not? (2018): subjective experience improved (responders) or not (non-reponders), better (not tested).

Shown, not counted: l-carnitine was given together with other treatments.

Combination: Folate / folic acid supplements + Vitamin B6 (pyridoxine, P5P) + Vitamin B12 + L-carnitine + Midodrine + Methylphenidate (Ritalin, Concerta)1 in the study

Comorbidity of chronic fatigue syndrome, postural tachycardia syndrome, and narcolepsy with 5,10-methylenetetrahydrofolate reductase (MTHFR) mutation in an adolescent: a case report (2021): symptoms, better (not tested).

Shown, not counted: l-carnitine was given together with other treatments.

See the 1 study
  1. Amantadine and L-carnitine treatment of Chronic Fatigue Syndrome. (1997)

    People in the study
    30 in the study · 28 started · 28 with outcome data
    Dose
    | g 3 times a day
    Outcome
    CFS-SI CFS Severity Index
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Studies of combinations

Outcomes that only studies of l-carnitine given together with other treatments looked at. Shown, not graded: they can’t tell what l-carnitine did alone.

Quality of life ME/CFS

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): individual measures of the SF-12, no clear difference.

Shown, not counted: l-carnitine was given together with other treatments.

Overall symptoms Long COVID

Combination: Nitric-oxide boosters (beetroot, arginine, citrulline) + L-carnitine + Baicalein and quercetin142 in the study

Peculiarities of clinical signs, course and treatment of musculoskeletal system lesions in post-COVID syndrome. (2023): better tolerance and action of NSAIDs, quicker regression of pain syndrome signs and other post-COVID signs, better (not tested).

Shown, not counted: l-carnitine was given together with other treatments.

Autonomic symptoms ME/CFS

Combination: Folate / folic acid supplements + Vitamin B6 (pyridoxine, P5P) + Vitamin B12 + L-carnitine + Midodrine + Methylphenidate (Ritalin, Concerta)1 in the study

Comorbidity of chronic fatigue syndrome, postural tachycardia syndrome, and narcolepsy with 5,10-methylenetetrahydrofolate reductase (MTHFR) mutation in an adolescent: a case report (2021): dizziness, better (not tested).

Shown, not counted: l-carnitine was given together with other treatments.

Side effects

Stopping because of side effects2 studies
Side effects studies reported3 kinds
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Nausea or stomach upset1 study
Trouble sleeping1 study
Worse symptoms or a flare1 study

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    1000 to 2000 mg at the start in most studies

  2. 2Top dose

    Most often 1000 mg (3 of 7 studies)

All papers

  1. Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome.2004 · randomised trial · 90 randomised
    Summary

    This open, randomized study enrolled 90 people with chronic fatigue syndrome according to CDC criteria from the polyclinic at the CFS Research Centre Amsterdam. Participants were assigned to three groups of 30: acetyl-L-carnitine 2 g/d, propionyl-L-carnitine 2 g/d, or acetyl-L-carnitine 2 g plus propionyl-L-carnitine 2 g, taken after breakfast and dinner for 24 weeks. The groups were compared with each other; no placebo group is reported. The primary measure was the clinical global impression of change, rated by patients. Secondary measures were the Multidimensional Fatigue Inventory, McGill Pain Questionnaire, and Stroop attention concentration test. After 24 weeks, improvement on the clinical global impression was reported by 59% in the acetylcarnitine group, 63% in the propionylcarnitine group, and 37% in the combined group; 10%, 3%, and 16% respectively felt worse. Two weeks after treatment stopped, worsening of CFS was reported by 52%, 50%, and 37%. Attention concentration improved significantly in all groups. Pain scores did not decrease significantly in any group. General fatigue improved significantly with propionylcarnitine (p = .004) and the combination (p = .000); mental fatigue improved with acetylcarnitine (p = .015). Eight patients stopped because of side effects—3 in the acetylcarnitine group, 2 in the propionylcarnitine group, and 3 in the combined group—with overstimulated feeling and sleeplessness. Another 8 stopped because they did not experience any effect—4, 1, and 3.

  2. Role of nutrient supplements in children with post-COVID condition: a retrospective preliminary observation and narrative review.2025 · compared with another group · 1,243 in the study · 1,171 with outcome data
    Summary

    This retrospective preliminary observation and narrative review asked whether nutrient supplements affected long COVID in children. It was a retrospective sub-analysis of a previously published prospective follow-up cohort at a Post-COVID clinic in a third-level hospital in Rome, Italy, from February 2020 to October 2022. During the study period 1243 patients were enrolled; 1171 were in the six-month follow-up table. Children with persistent, disabling symptoms at three months after infection received oral lactoferrin and/or a Multi-Element Product (MEP) as chewable tablets once a day for 90 days. Treatment groups were MEP plus lactoferrin (152 started), lactoferrin alone (18), and MEP alone (9). The outcome was persistence of long COVID at six months following initial infection. As reported, MEP alone (OR 5.7, 95% CI 3.8–8.5) and MEP plus lactoferrin (OR 5.06, 95% CI 3.3–7.6) were associated with a lower risk of long COVID at six months than lactoferrin alone (OR 7.6, 95% CI 5.1–11.4). For therapy started six months or longer after infection, no statistically significant associations were found with Long Covid resolution. Harms were not reported. The authors state the study was retrospective and had no control group, so causality and spontaneous improvement cannot be distinguished.

  3. Amantadine and L-carnitine treatment of Chronic Fatigue Syndrome.1997 · compared with another group · 30 in the study · 28 started · 28 with outcome data
  4. Patient-reported treatment outcomes in ME/CFS and long COVID.2025 · no comparison group · 5,451 in the study · 3,925 with outcome data
  5. Association between fatigue, peripheral serotonin, and L-carnitine in hypothyroidism and in chronic fatigue syndrome.2024 · no comparison group · 52 in the study · 40 with outcome data
    Summary

    This retrospective, non-randomized follow-up analysis examined whether oral L-carnitine supplementation was associated with fatigue and peripheral serotonin in chronic fatigue syndrome (CFS) and hypothyroidism with fatigue. The sample was consecutive patients seen by the senior author; 52 hypothyroidism patients and 16 CFS patients chose oral L-carnitine 300 mg twice a day for 7 weeks. The final analysed sample was 40 hypothyroidism and 12 CFS patients. Exclusions included SSRI use (7 hypothyroidism, 2 CFS), missing signed consent (5 hypothyroidism, 1 CFS), and 1 CFS patient removed during analysis after an autoimmune thyroiditis diagnosis. Each patient served as their own control; serum serotonin and fatigue were compared before vs after supplementation. Fatigue was measured with Question 1 of the BRAF-NRS, scored 0–10 with higher values worse after axis flipping. Fatigue decreased about 2-fold in hypothyroidism, from 6.7 (7.0) ± 0.9 to 2.4 (2.0) ± 1.0 (Sig. < 0.001), and in CFS, from 6.7 (7.0) ± 1.0 to 2.1 (2.0) ± 0.9 (Sig. = 0.002). No between-group comparison was reported. Side effects and withdrawals due to harms were not reported; the paper states there were no new diagnoses within 1 year or during L-carnitine supplementation.

  6. A novel frameshift mutation in ADCK1 identified in a case of chronic fatigue syndrome successfully treated with oral 5-ALA/SFC.2025 · case report · 1 in the study
    Summary

    This case report describes one 35-year-old Japanese woman with Chronic Fatigue Syndrome (CFS) who had experienced chronic fatigue since the age of 11 years. No comparison group was reported; the report describes a within-person clinical course over four years. The patient was treated with modafinil and methylphenidate beginning in 2012, levocarnitine at 1500 mg daily from November 2018, ubiquinone at 30 mg/day, and oral 5-ALA/SFC starting at 100 mg/day in January 2021. The 5-ALA/SFC dose was increased by 200 mg daily in February, to 300 mg/day in April 2021, and to 400 mg/day in January 2022; later attempts to reduce the dose in August 2022 to 200, 100, and 50 mg resulted in a significant decline in various activities. Outcomes included daily activities, mobility, psychosocial functioning, symptoms and quality of life, FACIT-F scores over time, daytime activity, daily functioning, various activities, sleep disturbances, and depression symptoms. The report states that 5-ALA/SFC led to significant improvements in daily activities, mobility, and psychosocial functioning; that the treatment regimen augmented with 5-ALA/SFC and ubiquinone led to significant improvements in symptoms and quality of life; and that returning to the 400 mg dose markedly improved all scores. Modafinil and methylphenidate proved ineffective for sleep disturbances, and antidepressants failed to improve depression symptoms. The patient continued 5-ALA/SFC for 4 years with no apparent adverse events; mild fever and chest discomfort were also reported. No withdrawals due to harms were recorded. Limitations include unavailable paternal DNA, uncertainty about the heterozygous mutation and CFS, and unclear long-term safety of 5-ALA/SFC.

  7. Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series.2025 · case report · 13 in the study
    Summary

    This patient-led case series documented the impact of extended-course oral nirmatrelvir/ritonavir in 13 individuals with established Long COVID. Participants came from public forums led by and for people with Long COVID or heard about the project by word-of-mouth. They took courses >5 days (range: 7.5–30 days): 11 outside the context of an acute infection (Cases 1–11) and 2 within an acute reinfection (Cases 12–13). There was no comparison group; participants reported symptoms and health experiences before, during, and after treatment. Some outside-acute participants experienced a meaningful reduction in symptoms, although not all benefits persist; others experienced no effect. The discussion states only 5 of the 13 cases experienced sustained improvement. Individual reports included no change, temporary improvement, return to pre-treatment baseline, and recurrence after stopping. One participant stopped early due to intense stomach pain. Reported harms included severe constipation and a severe MCAS flare, a severe “crash,” insomnia and taste-related side effects, dysgeusia, severe stomach pain with discontinuation, itchiness and tingling, dizziness and shakiness, and a PEM crash. For the two participants treated during acute reinfection, both report eventually returning to their pre-re-infection baseline. The authors list limitations: only 13 individuals who may or may not be representative; patient-reported experiences subject to recall or fatigue bias; and substantial heterogeneity in ages, symptoms, and treatment lengths.

  8. HERV Dysregulation in a Case of Myalgic Encephalomyelitis and Multiple Sclerosis Responsive to Rituximab.2025 · case report
    Summary

    This case report describes a single male patient in his 30s with a co-diagnosis of ME/CFS and MS, followed longitudinally. After a new MS relapse with radiological inflammation, he received rituximab at 1 g on days 1 and 15 of the first month, then nine monthly doses of 1 g adjusted by B-cell repopulation, a 9-month treatment regime. There was no comparison group; outcomes were before-versus-after observations in this patient. The report states a significant improvement in fatigue after the third dose, enabling increased mobility and participation in daily activities such as walking and dining out. On the Bell scale for severity assessment, the patient changed from a level of 10 to 20. After treatment he could leave the house 2–3 times a week and take gentle walks for an hour, and he reported a migraine once a month. The authors report he stayed in remission for at least 3 years after treatment. Harms of rituximab were not reported. The authors note limitations including sub-optimal frequency of MRI to monitor lesion progression and of HERV reassessment after rituximab, and the limited external validity of single study cases.

  9. Chronic fatigue syndrome (CFS) associated with Staphylococcus spp. bacteremia, responsive to potassium arsenite 0.5% in a veterinary surgeon and his coworking wife, handling with CFS animal cases.2001 · case report · 2 in the study
    Summary

    This preliminary note reports two patients with chronic fatigue syndrome: a 38-year-old veterinary surgeon (the author) and his 32-year-old co-working wife, both meeting the CDC working case definition. They fell ill in September 1992 after handling CFS animal cases. The study had no comparison group. Both received potassium arsenite 0.5% (Fowler’s solution 1/2), 1 ml/12 h intramuscularly for 10 days (7.5 mg of As/day), from 10 to 20 February 1996; no other medicament was given contemporaneously. Outcomes included symptoms, Bell’s Questionnaire radial plot scores, blood smears, blood cultures, CK, LDH and CD4/CD8 ratio. Following treatment, both patients experienced complete remission; at the post-treatment control 1 month later, micrococci had disappeared from the blood. Patient #1’s Bell score was 138.5 before and 44 after treatment; patient #2’s was 141.5 before and 8 after (the discussion also prints 141.4). Patient #1 had decreased weakness and improved exercise tolerance in a few days, and muscular and joint pain ceased by day 10. Patient #2’s premenstrual symptoms disappeared by day 4, and weakness and joint pain had completely disappeared by day 10. Neither patient suffered relapses during the following 5 years (1996–2001). Side effects and withdrawals were not reported. The authors state that species identification could not be performed.

  10. Peculiarities of clinical signs, course and treatment of musculoskeletal system lesions in post-COVID syndrome.2023 · combination: given with other treatments · 142 in the study
    Summary

    This study examined 142 patients aged 36–67 years with post-COVID syndrome and musculoskeletal system lesions from September 2020 to January 2022. In addition to a therapeutic complex, 102 patients in the main group received L-arginine (2,000 mg/day), L-carnitine (1,000 mg/day) and quercetin (240 mg/day) for three doses of medication, during 10–12 weeks; 40 patients who did not want to take them formed the comparison group. Check-ups were at 6 months (52 patients), 12 months (64 patients) and 18 months (26 patients). Table IV reported shorter times in the main group than the comparison group for reducing joint ache by half, complete disappearance of joint pain at rest, continuous and “as needed” NSAID use, and renewing tolerance to moderate physical exertion, in both age subgroups, with p < 0.05. Relapses were reported in 2 (3.08%) older main-group patients and 4 (10.0%) comparison patients; the under-50 main-group cell was printed as “–”. After 6 months, 65 patients with arthritis without age-related X-ray changes had no complaints or objective joint signs, and all patients with arthralgia and myalgia had no complaints. After three months, patients reported decreased tolerance, shortness of breath and less often dry cough. After 8–12 months, 19 out of 27 patients with X-ray osteoarthritis stage I–II had exacerbation. Withdrawals due to harms were not reported.

  11. Proposal of a food supplement for the management of post-COVID syndrome.2021 · combination: given with other treatments
    Summary

    This paper reviews what is known about post-COVID syndrome and nutritional approaches, and reports a small pilot observational study. People who had recovered from COVID-19 but had post-COVID syndrome with chronic fatigue took a food supplement containing hydroxytyrosol, acetyl L-carnitine and vitamins B, C and D, and their perceived fatigue was assessed. The abstract gives no number of participants, no length of treatment, no fatigue scores and no side effects. The authors write that the results suggest the supplement could go on to clinical trials.

  12. Comorbidity of chronic fatigue syndrome, postural tachycardia syndrome, and narcolepsy with 5,10-methylenetetrahydrofolate reductase (MTHFR) mutation in an adolescent: a case report2021 · combination: given with other treatments · 1 in the study
    Summary

    This case report describes one 16-year-old male adolescent hospitalized with intermittent dizziness, drowsiness, and fatigue for approximately 2 years, diagnosed with chronic fatigue syndrome with narcolepsy, POTS, and hyperhomocysteinemia associated with MTHFR mutation. There was no comparison group. He was given oral folate 5 mg/day, vitamin B6 10 mg/day, vitamin B12 0.5 mg/day, and l-carnitine 1 g/day continuously; oral midodrine hydrochloride 7.5 mg/day was added. After 1 month of therapy, the report states dizziness was relieved to a certain extent, but drowsiness and fatigue barely improved. Methylphenidate hydrochloride tablets 18 mg/day were then added. After another month, the patient felt much less drowsy during the daytime, and total sleep duration shortened to 9 to 10 h/day from a reported 14 to 15 h/day. He began to gradually resume school life and maintained a normal sleep rhythm since then. The report also states narcoleptic symptoms were controlled by methylphenidate hydrochloride and symptoms improved after the combined therapy. No harms or withdrawals were reported. The authors state that the mechanisms by which MTHFR gene polymorphism plays a role in CFS still need to be studied.

  13. Why do some ME/CFS patients benefit from treatment with sodium dichloroacetate, but others do not?2018 · combination: given with other treatments · 35 in the study
    Summary

    In a prospective trial including 35 ME/CFS patients, 25 females and 10 males with mean age 42.5 years (SD 9.6 years) and mean disease duration 8.7 years (SD 4.6 years), patients consulting at the private clinic of the author took one tablet per day of a nutraceutical containing 400 mg of sodium dichloroacetate (DCA) together with vitamin B1, oxidoreductase Ubiquinone Q10, alfa lipoic acid and acetyl-l carnitine. After 4–6 weeks of intake, patients reported their subjective experience as improved (responders, n = 13) or not (non-responders, n = 22) and completed the Fatigue Severity Scale again. There was no separate comparison group; responders were compared with non-responders. In the cohort, 22.9% had auto-immunity with a positive titre of anti-nuclear antibodies (ANA) of 1/80 or more; 25% of that group were responders, compared with 41% of patients without auto-antibodies (difference not significant; P = 0.69). Logistic regression discrimination had an area under the ROC curve = 0.92 (95% confidence interval: 0.78–0.99), P < 0.0001, with specificity of 86% and sensitivity of 84%. Mean fatigue score was 6,00 before and 3,70 after in responders, and 6,23 before and 6,15 after in non-responders. No adverse effects were recorded.

  14. Treating patients suffering from myalgic encephalopathy/chronic fatigue syndrome (ME/CFS) with sodium dichloroacetate: An open-label, proof-of-principle pilot trial.2018 · combination: given with other treatments · 22 in the study
    Summary

    This open-label, prospective pilot trial treated 22 consecutive patients (14 women, 8 men, mean age 43.3 years, SD: 10,7 years) with refractory and long-lasting ME/CFS, diagnosed by reference centres, with an innovative nutriceutical containing sodium dichloroacetate (DCA). The initial 10 patients received 400 mg of sodium salt of dichloroacetate (DCA) plus 100 mg Vitamin B1, taken one capsule per day for 30 capsules; afterwards the formulation was extended by adding alfa-lipoic acid (ALA), acetyl-l-carnitine and the oxidoreductase ubiquinone Q10. Fatigue was measured with the Fatigue Severity Scale before treatment and after 30 days. Ten patients (45%) responded favourably: their FSS decreased from an average of 6.00 points (SD: 0.68) to 3.48 points (SD: 0.98), a decrease of 42.7% (SD:17.8%; P=0.0001). In the 12 non-responders the FSS was 6.43 points (SD: 0.47) before treatment and 5.96 (SD:1.06) after treatment (P=0.13). In 2 responders with important fibro-myalgic complaints the pain visual scale value decreased from 8 to 2, and from 6 to 2 respectively; responders also noticed important improvement of the cognitive functions, not evaluated by any specific test. One responder experienced generalised moderate tremor, which disappeared immediately after the dose of DCA was decreased. The authors state the trial is open-label with a small number of patients and that the findings need to be challenged by a larger prospective double-blind trial.

  15. Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study2017 · combination: given with other treatments · 10 in the study
    Summary

    This 16-week open-label pilot study examined a combination nutraceutical of mitochondrial agents in 10 patients with chronic fatigue syndrome recruited through clinicians and based at The Melbourne Clinic in Melbourne, Australia. Participants received twice-daily dosing of Co Q10, alpha lipoic acid, N-acetylcysteine, Acetyl L-carnitine, B vitamins and co-factors for 16 weeks, with no placebo comparison. Assessments occurred at baseline, W4, W8, W12 and W16 and included the Chalder Fatigue Scale (CFQ), MADRS, ISI, PGI, CGI-S, CGI-I, WSAS and SF-12. Mean total CFQ scores fell from 22.0 (6.07) at baseline to 12.6 (7.46) at Week 16 (F(4,29) = 6.31, p < 0.001); the baseline-to-Week 4 mean difference was 7.66 (p < 0.01). Nine of 11 CFQ items showed significant improvement, while memory (item 11) and problems starting things (item 4) did not. ISI (p = 0.017) and CGI-I (p = 0.014) improved; MADRS (p = 0.225), PGI (p = 0.33), CGI-S (p = 0.150), WSAS (p = 0.095) and SF-12 measures did not change significantly. Adverse events included headaches/migraines (n = 3), minor gastritis (n = 4), loss of appetite/feeling of fullness (n = 1), brief tachycardia (n = 1) and skin pigmentation on the forehead (n = 1); no serious adverse events were noted, and no participants withdrew due to adverse events. Two participants (20%) withdrew before termination, at week four and week twelve, due to work commitments.

  16. Attenuation of autoimmune responses to oxidative specific epitopes, but not nitroso-adducts, is associated with a better clinical outcome in Myalgic Encephalomyelitis/chronic fatigue syndrome.2014 · combination: given with other treatments · 76 in the study
    Summary

    Seventy-six ME/CFS patients admitted to the Maes Outpatient Clinics, Belgium, were selected for increased (> 2 SD) IgM responses to 3 OSEs or 3 NO-adducts. In this non-interventional study, all patients took a combination of NAIOS—L-carnitine, coenzyme Q10, taurine + lipoic acid, with or without curcumine + quercitine or N-acetyl-cysteine, zinc + glutamine—continued for 14.3 (±4.2) months. There was no separate comparison group; patients also received other care-as-usual treatments. The study measured FF scores and IgM responses to oleic acid, MDA, Pi, NOW, NO-arginine and NO-cysteinyl. Treatment was followed by significant reductions in IgM responses to oleic acid (F=9.03, p=0.004), MDA (F=13.12, p=0.001), Pi (F=20.28, p<0.001), NO-Cysteinyl (F=10.03, p=0.003), NO-Arginine (F=6.99, p=0.011) and NOW (F=6.19, p=0.016). In patients with endpoint FF<12, oleic acid and Pi responses fell more than in those with endpoint FF≥12. Antidepressant use had no significant effect (F=0.17, p=0.843). Harms were not reported. The authors state the non-interventional design could not standardize NAIOS and that supplement quality, content and bioavailability may have biased results.

  17. Normalization of the increased translocation of endotoxin from gram negative enterobacteria (leaky gut) is accompanied by a remission of chronic fatigue syndrome.2007 · combination: given with other treatments · 1 in the study
    Summary

    This case report from Belgium describes one 13-year-old girl with chronic fatigue syndrome (CFS) who was unable to walk or stand and had muscle pain and weakness. She received a combined treatment: antioxidants (L-carnitine, CoQ10, lipoic acid, taurine), a supplement containing L-glutamine, gamma oryzanol and zinc, a specific “leaky gut diet”, and intravenous immunoglobulins (IVIg; sandoglobuline 6 g/day during 1 month, and thereafter 6 g each two weeks for the following months). No comparison group was reported. The paper reports clinical symptoms and serum IgM against the LPS of gram-negative bacteria. During December 2005 to May 2006, no change in the clinical picture could be detected. On August 18, 2006, she regained strength, her concentration was much better and she could read books again, her sleep disorders were much better, and she had restarted swimming classes; she still suffered from non-refreshing sleep and abdominal complaints. On December 8, 2006, her clinical condition was again much better, her sleep became refreshing, and abdominal complaints including bloating were better, although sometimes she had diarrhea and nausea; during one week she had suffered from sore throat and tender lymph nodes. On February 1, 2007, she ascertained that all her symptoms had disappeared. IVIg was stopped, while antioxidants and the leaky gut diet were continued. On July 13, 2007, she finished the school year with a very good score (>80%). By November, 2007, all CFS symptoms were still in remission. No limitations were stated in the supplied text.

  18. Dietary Supplementation for Fatigue Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)-A Systematic Review.2025 · systematic review
    Summary

    This systematic review asked whether dietary supplements reduce fatigue in ME/CFS. It included 14 studies (7%) identified from 189 papers searched in Ebsco Host, PubMed, Scopus, and Google Scholar; the final search was 7 May 2024. Supplements varied and included ImmunoVita®, Supradyn®, probiotics, CoQ10 with selenium or NADH, GAA, carnitine, AEO, and acclydine; treatment periods reported in the text included 36 weeks and ten weeks. Comparisons varied across the included studies. Outcomes were mainly self-report fatigue questionnaires plus quality of life, activity, and laboratory markers. Findings were mixed: some supplements were reported to reduce fatigue scores or improve cognitive fatigue, while others showed no significant fatigue changes; AEO was reported to reduce fatigue for 22–33% of participants, ENADA® showed improvement in 31%, and ALC/PLC was followed by worsening symptoms in many patients. Six out of fourteen studies reported adverse effects, including nausea, dyspepsia, insomnia, and others. The authors state no firm conclusions can be drawn due to small sample sizes and missing data, and note limitations such as focusing on fatigue as the only primary outcome.

  19. Clinical effectiveness of rehabilitation in ambulatory care for patients with persisting symptoms after COVID-19: a systematic review.2023 · systematic review
    Summary

    This systematic review asked whether rehabilitation treatments applicable in ambulatory care help adults with persisting symptoms after COVID-19. Searches on 9 May 2022 identified 45,479 records, and 38 studies comprising 2,790 participants were included. Interventions included physical training, breathing exercises, nutritional supplements, olfactory training, multidisciplinary treatment, and other treatments such as hyperbaric oxygen therapy; treatment duration was not reported. Comparisons varied, including low- versus high-intensity training in 76 men and advanced versus classical olfactory training in 80 patients. Outcomes included fatigue, dyspnoea, pain, physical capacity, pulmonary function, sensory function, quality of life, return to activities, functional capacity, and adverse events. Physical training and breathing exercises may reduce fatigue, dyspnoea, and chest pain and may improve physical capacity and quality of life, with very weak evidence; improvement was not demonstrated for muscle pain or return to work. Low-intensity training increased handgrip strength and quality of life compared with high-intensity training. Advanced olfactory training was not superior to classical training. Hyperbaric oxygen therapy can have beneficial effects on fatigue in one cohort of 10 patients. Side effects with olfactory training occurred in 18 out of 80 participants. Reported adverse events included hospitalisations, dizziness, symptom exacerbation such as fatigue, headache in one participant, and post-exertional malaise after exercise.

  20. Dietary and nutrition interventions for the therapeutic treatment of chronic fatigue syndrome/myalgic encephalomyelitis: a systematic review.2017 · systematic review
    Summary

    This systematic review asked whether dietary and nutrition interventions affect patient-centred outcomes in adults with CFS/ME. Medline, Cinahl and Scopus were searched from 1994 to May 2016; 17 studies were included, covering 14 different interventions. Included studies were mostly small and from multiple countries. Interventions included ubiquinol-10 150 mg/day for 12 weeks versus placebo; NADH 200 mg/day plus CoQ10 20 mg/day for 8 weeks versus placebo; high cocoa polyphenol chocolate for 8 weeks versus low-polyphenol chocolate; NADH 10 mg/day for 4 weeks versus placebo; probiotics; and an elimination diet. Outcomes were fatigue, quality of life, physical activity and psychological wellbeing. The review reports that many studies did not show therapeutic benefit; improvements in fatigue were observed for NADH, probiotics, high cocoa polyphenol rich chocolate, and a combination of NADH and coenzyme Q10. One included study (n=10) reported decreased fatigue with high cocoa polyphenol chocolate, and one (n=26) reported within-group benefit for NADH versus placebo. Side-effect counts and counts of people who worsened or stopped were not reported. The authors conclude there is insufficient evidence for nutritional supplements and elimination or modified diets to relieve CFS/ME symptoms.

  21. A Systematic Review of Drug Therapies for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.2016 · systematic review
    Summary

    This systematic review examined drug therapies for chronic fatigue syndrome or myalgic encephalomyelitis (CFS/ME). Ovid MEDLINE, EMBASE, and PubMed were searched from the beginning of their archives to March 2016. The review included 26 randomized, placebo-controlled trials that met its criteria; these trials tested 20 drug therapies. The review reports effectiveness by categories from not effective to highly effective and says no universal pharmaceutical treatment can be recommended. Hydrocortisone findings were conflicting: across studies it was reported as mildly effective, slightly effective, not effective, and moderately effective; in one study the well-being improvement was not significant, and Blockmans et al found no clinical improvement. Rituximab was reported to produce a significant and lasting improvement, but the review states it is premature to conclude a lasting improvement in primary assessed domains; primary end points were evaluated for 3 months and secondary end points up to 12 months. For intravenous immunoglobulin, Rowe reported headache, fatigue, and difficulty concentrating significantly worse in the intervention group after the first infusion, with no differences after the third and final infusion. The review states no pharmaceutical therapy resulted in severe adverse events. It notes nefazodone was discontinued in 2004 after patients developed hepatic and visual disorders. Forsyth et al and Young each had N = 26; Young lacked male participants in the intervention cohort. The authors state that no clear recommended pharmaceutical therapy for CFS/ME exists and call for standardized diagnostic criteria and outcome measurements.

  22. Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop.2015 · systematic review
    Summary

    This systematic review examined treatments for adults with ME/CFS. It included 35 treatment trials in 45 publications; trials enrolled predominantly middle-aged women from ME/CFS specialty clinics and used CFS case definitions. Treatments were compared with placebo, usual care, wait-list, relaxation, adaptive pacing, CBT, or other therapies. In 2 fair-quality trials (n=324), rintatolimod improved cardiopulmonary exercise test tolerance (36.5% versus 15.2%; P=0.047), exercise duration (10.3% versus 2.1%; P=0.007), and exercise work (11.8% versus 5.8%; P=0.01). In a small trial of 30 participants, valganciclovir improved fatigue on 1 scale but showed no statistically significant differences for other measures. Trials of galantamine, hydrocortisone, IgG, isoprinosine, and fluoxetine indicated no beneficial effects but were limited by small numbers. Counseling and behavior therapies improved fatigue, function, quality of life, work impairment, and global improvement in some trials (low to moderate strength of evidence). A meta-analysis of 4 CBT trials found no statistically significant difference in SF-36 physical function (weighted mean difference, 10.42 [95% Cl, -3.86 to 24.69]); a sensitivity analysis found 6.02 [Cl, 1.05 to 10.88]. GET improved function (10.68 [Cl, 6.32 to 16.88]), fatigue (4 trials, n=619), and global improvement (relative risk, 1.58 [Cl, 1.24 to 2.47]). In the PACE trial, deterioration of physical function was 25% with adaptive pacing, 18% with usual care, and 11% with GET (P<0.001). Harms included galantamine: 90% reported harms and 2% serious events, none attributed to study drug; IgG headaches 93% versus 60%; GET serious adverse events 17 versus 7. GET withdrawals were 37% versus 22%, and 20% declined repeat exercise testing. Adverse effects were rarely reported overall.

  23. Complementary and alternative medicine for patients with chronic fatigue syndrome: a systematic review.2011 · systematic review
    Summary

    This systematic review examined randomised controlled trials of complementary and alternative medicine (CAM) for patients with chronic fatigue syndrome (CFS), also termed myalgic encephalomyelitis (ME). The search was up to 13th August 2011. A total of 26 RCTs, which included 3,273 participants, met the inclusion criteria. The CAM therapies included mind-body medicine, distant healing, massage, tuina and tai chi, homeopathy, ginseng, and dietary supplementation. The review reports that studies of qigong, massage and tuina demonstrated positive effects, whereas distant healing failed to show a significant effect on mental or physical components of quality of life. Compared with placebo, homeopathy had insufficient evidence of symptom improvement in CFS. Most supplements failed to show beneficial effects for CFS, with the exception of NADH and magnesium. Five of the 26 included studies reported no adverse events or a slight occurrence of them, and the other included studies lacked descriptions regarding adverse events; no severe adverse effects of CAM were noted. The authors state that firm conclusions are difficult with the limited number of RCTs for each therapy, small sample sizes and high risk of bias.

  24. Alternative medical interventions used in the treatment and management of myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia.2010 · systematic review
    Summary

    The review included 70 controlled clinical trials of alternative and complementary treatments and nonpharmacological supplements for ME/CFS and fibromyalgia; searches ran up to April 2007. It did not have its own treatment arm or comparison group; it summarized trials with control or comparison conditions. The review did not report one treatment dose or duration. Outcomes in included trials covered laboratory tests, physical functioning, psychologic functioning, and quality of life. The review reports that some trials showed at least one positive effect and some showed null or ambiguous results; it states that no firm conclusions can be made. Only three studies (4%) reported adverse side-effects such as bruising and rashes. For acupuncture, three RCTs reported dropout rates of around 15%–35% in all intervention groups. The authors state publication bias: beneficial effects tend to be published while negative results may remain unpublished. They also state the methodological quality of reporting was generally poor and that no definite CAM treatment recommendations can be made for ME/CFS or FM.

  25. Interventions for the treatment, management and rehabilitation of patients with chronic fatigue syndrome/myalgic encephalomyelitis: an updated systematic review.2006 · systematic review
    Summary

    This updated systematic review asked whether any intervention is effective for treatment, management or rehabilitation of adults and children with CFS/ME. The authors searched eleven electronic databases and included 70 studies, of which 59 were RCTs; comparisons were between treatment and control groups. Interventions included CBT, GET, rehabilitation, immunological and pharmacological treatments, supplements and complementary therapies. Outcomes covered physical, psychological, laboratory/physiological and quality-of-life measures. CBT and GET appeared to reduce symptoms and improve function based on RCTs. In a CBT trial (n=69), physical functioning, fatigue and symptoms favoured CBT (P<0.003) and school attendance favoured treatment (P=0.04). Another CBT trial (n=65) found no significant difference for fatigue, anxiety and depression, or disability. In GET trials, CGI and fatigue favoured treatment (n=49; P<0.03), and fatigue and depression/anxiety were significantly better (n=61; P=0.027). One GET trial reported withdrawal of one patient in each group because of worsening symptoms; eleven patients withdrew because of adverse events in a GET with or without fluoxetine trial. Galantamine (n=434) showed no significant differences; 130 patients withdrew, 389 reported adverse events and 88 withdrew. Acetyl-L-carnitine and propionyl-L-carnitine (n=90) improved general fatigue in PLC (P=0.004) and combined group (P<0.001), and mental fatigue in ALC group (P=0.015); 8 patients withdrew due to side effects. Staphylococcus toxoid (n=98) had 13 treatment-group and 7 placebo-group patients with side effects. Hydrocortisone/fludrocortisone (n=80) found no significant differences.

  26. Micronutrition as a Therapeutic Strategy for Mitochondrial Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia: A Narrative Review.2026 · review
    Summary

    This narrative review asked why mitochondrial dysfunction, redox imbalance, and immune–metabolic dysregulation may contribute to fatigue in fibromyalgia and ME/CFS, and it examined mechanistic and clinical evidence for mitochondrial-oriented micronutrition. No patients were enrolled, started, or analysed; the authors did not give any treatment, did not compare groups, and did not measure outcomes. The work is a structured, non-systematic literature search of PubMed/MEDLINE, Scopus, and the Cochrane Library for English-language publications up to 31 January 2026. It discusses NAD+ precursors, B-complex vitamins, magnesium, coenzyme Q10, alpha-lipoic acid, GlyNAC, L-carnitine, pyrroloquinoline quinone, taurine, and creatine. Findings described from cited studies include improved fatigue-related and quality-of-life outcomes with combined CoQ10 and NADH in ME/CFS; no significant pain improvement with ALA in fibromyalgia; improvements in pain and stress-related outcomes but not fatigue, sleep, or quality of life with magnesium; increased muscle strength but no significant improvement in pain, cognitive function, sleep, or quality of life with creatine; and improved fatigue-related outcomes with carnitine in an exploratory study without a placebo group. The review reports no side effects, withdrawals, or worsening for its own study because it has no participants. The authors state that clinical evidence varies and is limited by heterogeneous studies and generally low-to-moderate certainty.

  27. Exploring the Potential of Dietary Supplements to Alleviate Pain Due to Long COVID.2025 · review
    Summary

    This review explored dietary supplements for pain due to long COVID. It was a review, not a randomised trial; it had no comparison group, and the review itself did not report enrollment, setting, or follow-up. It summarized studies in long COVID or post-COVID syndrome, including studies with 60, 33, 69, 1, 463, 39, 51, 80, 53, 20, and 12 participants. Treatments included acetyl-l-carnitine 500 mg/day, palmitoylethanolamide 600 mg twice daily, PEA-LUT 770 mg, SIM01, VSL#3®, a vitamin D–containing supplement, vitamin D, marine oil enriched in SPMs, a multinutrient supplement, NAC plus guanfacine, and metformin. Durations reported in the recorded findings included 2 weeks, 4 weeks, 6 months, and 10 months. Measured outcomes included pain, persistent post-COVID symptoms, smell recovery, fatigue, memory loss, concentration, gastrointestinal upset, general unwellness, cognitive abilities, physical functioning, anxiety, depression, and long COVID risk. Findings included improvements in pain, fatigue, cognitive symptoms, smell, and some quality-of-life domains; one report noted no improvement in anxiety, depression, performance, or somatization. Recorded side effects were minimal side effects with vitamin D and mild adverse events with LDN; another recorded harms statement concerned antidepressants, and 19 participants discontinued because of adverse events (12 gabapentin, 7 placebo). The authors stated that clinical experience in long COVID-associated pain is still limited.

  28. Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): diagnosis and management.2025 · review
    Summary

    This narrative review searched PubMed, Web of Science, Embase, and the Cochrane Library from inception to August 2025 and included 211 publications on ME/CFS diagnosis, pathophysiology, assessment, and treatment. It summarized pharmacological and non-pharmacological interventions. Reported examples include a double-blind, randomized, placebo-controlled trial of IVIG in 99 CFS patients that found an absence of dose-dependent efficacy; a Phase III rintatolimod study in 208 ME/CFS patients in which 51.2% of a severely debilitated subgroup (n = 21/41) had a ≥ 25% improvement in exercise treadmill test duration; a 12-week trial in 207 ME/CFS patients reporting significant reductions in fatigue with CoQ10 (200 mg) and nicotinamide adenine dinucleotide (20 mg); LDN showing significant improvement in 73.9% of 218 ME/CFS patients; and a pilot study of 55 ME/CFS patients in which oral minocycline produced favorable symptom improvements for 80% of treatment completers. A pooled analysis of 1,298 ME/CFS patients from eight trials associated CBT with significant reductions in fatigue severity and functional impairment. A pragmatic trial in 241 adolescents (aged 8–17) found no significant inter-group difference between GET and activity management for physical function on the Short-Form 36 at 6 months. A systematic review and meta-analysis reported a significant reduction in fatigue (Hedges’ g = -0.52) and an improvement in physical function with pacing compared with no treatment or routine care. Harms included GET-associated symptom exacerbation in a significant proportion of patients, and rintatolimod adverse events may occur. TCM findings should be cautiously interpreted because the available evidence is constrained by methodological limitations.

  29. A Comprehensive Scoping Review on Diet and Nutrition in Relation to Long COVID-19 Symptoms and Recovery.2025 · review
    Summary

    This scoping review synthesized 50 studies (27 intervention and 23 observational) in adults with long COVID-19, identified through database and manual searches. The review itself had no comparison group and no meta-analysis. Included studies examined vitamin D, multinutrient/nutraceutical formulations, amino acids and metabolic support, creatine, oxaloacetate, nitric-oxide boosters, gut microbiota-targeted therapies, and diet/lifestyle programs; comparisons included placebo, controls, or another formulation. Examples reported: in 80 people with post-COVID-19 syndrome, weekly vitamin D improved fatigue (p = 0.024), anxiety (p = 0.011), and cognitive function (p = 0.012), with no effects on depression, sleep quality, or inflammatory markers. A single 200,000 IU vitamin D3 dose in 144 hospitalized patients showed no benefit on persistent symptoms or quality of life. Magnesium plus vitamin D improved depression (73.2% vs 34.5% remission, p = 0.006). PIRV-F20 in 44 long COVID-19 patients improved six-minute walking distance (+40 m vs +10 m, p = 0.02) but not strength or symptoms. Noni in 188 post-COVID-19 patients reduced fatigue (61.5% vs 24.3%), cognitive symptoms (59.4% vs 21.6%), and joint pain (66.2% vs 33.8%). SIM01 in 463 individuals alleviated core symptoms (all p < 0.01). Beetroot juice in 31 patients showed no significant between-group differences. Side effects and withdrawals were not reported in the recorded data. The authors state no formal quality appraisal was performed and causal inferences cannot be made.

  30. Neuropsychiatric Manifestations of COVID-19 Disease and Post COVID Syndrome: The Role of N-acetylcysteine and Acetyl-L-carnitine.2025 · review
    Summary

    This narrative review aimed to summarise evidence on the potential therapeutic role of N-acetylcysteine (NAC) and acetyl-L-carnitine (ALC) in neuropsychiatric manifestations of COVID-19 and Post COVID Syndrome, and to propose a pathophysiological model. It covers acute COVID-19, ongoing symptomatic COVID-19, PCS, and overlap with CFS. The setting is not reported. No patients enrolled, started, or analysed are reported, and no comparison group, randomisation, crossover, or follow-up is reported. The review did not administer a treatment or report a treatment duration. It discusses NAC and ALC mechanisms and cites a randomised study by Scaturro et al. in which ALC was used for depressive symptoms associated with Long COVID; patient numbers are not reported. The review reports no own results, no between-group results, no harms, no withdrawals, and no side-effect counts. Its conclusions state that NAC reduces KYNA levels, potentially ameliorating COVID-related cognitive dysfunction; that ALC was found effective in treating depressive symptomatology of PCS; that ALC and NAC could ameliorate fatigue through different mechanisms, including combined glutamatergic action; and that NAC and ALC hold promise for neuropsychiatric conditions associated with COVID-19 and PCS. The authors state that the speculative nature of their inferences must be considered.

  31. Conceptual foundations of acetylcarnitine supplementation in neuropsychiatric long COVID syndrome: a narrative review.2024 · review
    Summary

    This narrative review examined acetylcarnitine as a possible treatment for neuropsychiatric long COVID, with discussion of ME/CFS and major depressive disorder. It did not report its own enrolled participants, setting, or follow-up. The review summarized an open-label, randomized trial in patients with ME/CFS in which acetylcarnitine supplementation at 2 g/day for 24 weeks improved mental fatigue. It also summarized an observational case–control study in post-COVID syndrome reporting improvements in quality of life, depressive complaints, and pain scores after 1 month of combined physical exercise and acetylcarnitine supplementation at 0.5 g/day for 4 weeks compared with physical exercise alone. A study of patients with long COVID syndrome reported a decrease in fatigue and an increase in subjective energy levels after 2 weeks of a supplement containing 150 mg of acetylcarnitine. Side-effect counts and withdrawals were not reported for these acetylcarnitine studies. The authors state preliminary evidence for benefit in long COVID but no clear evidence that acetylcarnitine alone improves neuropsychiatric symptoms, and they call for further trials.

  32. Nutritional And Dietary Interventions For The Treatment Of Chronic Fatigue Syndrome2018 · review
    Summary

    This review asked whether nutritional and dietary interventions can minimize symptoms of chronic fatigue syndrome (CFS/ME); 22 researches from EBSCO and Google Scholar were analyzed. It describes Castro-Marrero et al. 2015: 113 patients were enrolled at the CTS Clinical Unit (Vall d'Hebron Hospital, Barcelona, Spain); after 8 weeks of CoQ10 and NADH treatment, fatigue in people with CFS decreased compared to placebo. Ostojic et al. 2016 gave GAA (2.4 g per day) or placebo for three months: general fatigue and musculoskeletal pain were not affected; muscle and oxygen strength improved; daily physical activity and active energy expenditure were ineffective; GAA reduced physical and mental fatigue; a significant effect on muscle pain and fatigue was not reported; no side effects were reported. Rao et al. 2009 observed a reduction in aggression after 8 weeks of Lactobacillus casei Shirota. Vermeulen et al. 2004 studied 90 patients with CFS for 24 weeks: improvement was 59% in the ALC group, 63% in the PLC group and 37% in the ALC + PLC group; 10% in the ALC group, 3% in the PLC group and 16% in the ALC + PLC group felt worse; after 2 weeks of discontinuation, 52% in the ALC group, 50% in the PLC group and 40% in the ALC + PLC group deteriorated; 8 patients were excluded due to side effects (3 in the ALC group, 2 in the PLC group and 3 in the ALC+PLC group) because they experienced excessive excitability and insomnia. Limitations: relatively small experiments.

  33. Treatment and management of chronic fatigue syndrome/myalgic encephalomyelitis: all roads lead to Rome.2017 · review
    Summary

    This comprehensive review examines benefits and harms of treatments for CFS/ME and makes recommendations. It reports no single enrolled or analysed total. Among the included studies, a phase II rintatolimod trial had 92 patients and a phase III trial had 234 patients; a rituximab RCT had 30 patients, with sustained overall improvement in 67% of CFS/ME patients versus 13% of controls. The PACE trial had 640 patients; a recovery paper reported 22% recovered in the CBT and GET groups, compared with 8% in the APT group and 7% in the SMC-only group. A survey of 828 Norwegian CFS subjects reported pacing useful in 96%, and 79% of patients with experience of graded training considered it worsened their health. CoQ10 plus NADH was studied in 80 patients, with maximum heart rate p=0.022. The review also describes harms: three patients administered acyclovir withdrew due to reversible renal failure, and two out of 13 participants developed neutropenia. The authors state no firm conclusions can be drawn because the few RCTs were small-scale, with a high risk of bias, and used different case definitions; nutritional studies were very limited, mostly small and without long-term follow-up.

  34. Clinical Uses of Membrane Lipid Replacement Supplements in Restoring Membrane Function and Reducing Fatigue in Chronic Diseases and Cancer.2016 · review
    Summary

    This review asked whether oral Membrane Lipid Replacement (MLR) supplements reduce fatigue and affect membrane and mitochondrial function across chronic conditions. It reports several clinical studies; one non-open label exception was a cross-over trial of oral NTFactor® in 22 moderately to severely fatigued subjects. In that trial, after 12 weeks of NTFactor® supplementation, mitochondrial function was similar to that found in young healthy adults (26.8% increase, p<0.0001), and fatigue was reduced 35.5% (p<0.001); after 12 weeks of supplement use, subjects were placed on placebo without their knowledge for an additional 12 weeks, and fatigue and mitochondrial function were intermediate between starting values and values after 12 weeks on the supplement. Table 1 lists fatigue reductions for Propax/NTFactor® in chronic fatigue (34 patients; Reduction (%)b: 40.5 §), NTFactor® in CFS/fibromyalgia (15; 43.1 *), Healthy Curb® in obesity/fatigue (35; 23.9 *), APF/NTFactor® in aging/chronic fatigue (67; 36.8 §), Propax/NTFactor® in cancer/fatigue (35; 30.1 *), ATP Fuel®/NTFactor® in CFS/ME (30; 30.7 §), Gulf War illness (16; 34.6 *), and Lyme disease (17; 26.0 *). ATP Fuel® studies reported significant fatigue reductions within 6 weeks (p<0.0001). A 36-patient chemotherapy cross-over trial reported fewer adverse effects of therapy. Adverse effects: older subjects receiving over 2 g per day of oral glycerolphospholipids (NTFactor®) for over 6 months showed no adverse effects of the MLR phospholipids; the review states no evidence of toxicity or adverse events from long-term MLR glycerolphospholipids. Limits: the authors call for additional controlled trials.

  35. Chronic fatigue syndrome: is there a role for non-antidepressant pharmacotherapy?2010 · review
    Summary

    This review examined pharmacotherapy for chronic fatigue syndrome (CFS), also called myalgic encephalomyelitis (ME), focusing on non-antidepressant controlled drug trials published between 1988 and August 2009. It did not report one overall number of enrolled patients. In the methylphenidate trial (60 CFS patients), clinically significant improvement on the Checklist of Individual Strength concentration subscale occurred in 13 patients taking methylphenidate (22%) versus three taking placebo (5%; p = 0.01); the number needed to treat was 6 [95% CI: 4.6 to 8.6]. A clinically significant fatigue response occurred in 10 patients (17%) with methylphenidate versus no patients with placebo; the number needed to treat was 6 (95% CI: 3.8 to 14.4). No effect was observed on bodily pain, mental health, depression and anxiety, and no severe side effects were reported. Other reviewed trials reported no significant effect for aciclovir, no beneficial effects for ganciclovir, no differences versus placebo for oral terfenadine (n = 30), and no effect for immunoglobulin in a large RCT (n = 99). In a doxycycline RCT (n = 491), there were no statistically significant differences versus placebo; the doxycycline group had a higher incidence of nausea and photosensitivity. Two participants in a magnesium RCT (n = 34) dropped out, one because of generalized rash.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime